Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Measurements of technological accuracy are important when selecting speech-recognition software, but comparisons are accuracy measurements are moot since there is no standardized way to measure these rates, according to a whitepaper released by Franklin, Tenn.-based M*Modal.
The global medical imagining equipment market is expected to reach $35.35 billion by 2019, growing at a compound annual growth rate of 5.4 percent, according to a news release from Transparency Market Research.
Mortsel, Belgium-based Agfa Healthcare has announced the first sales of its IMPAX Agility picture archiving and communication system in the United States.
Alpharetta, Ga.-based MedAssets has renewed two of its major partnerships with Oakland, Calif.-based Kaiser Permanante and Richmond University Medical Center in Staten Island, N.Y.
Brentwood, Tenn.-based HealthTrust is now a supporting member of the Healthier Hospitals Initiative, a collaboration of healthcare organizations pushing the industry to become more environmentally sustainable, according to a HealthTrust news release.
The global ophthalmology drugs and devices market is expected to reach $52.6 billion by 2017, according to a report released by MarketsandMarkets.
The sex ratio in post-approval studies mandated by the U.S. Food and Drug Administration varies greatly in certain clinical areas, even reaching an imbalance of nine females to every one male, according to a study published in the Journal of…
Hospitals are experiencing a shortage of intravenous fluid, specifically saline solution, due to an increased demand possibly spurred by the onset of the flu season.
Morehead Memorial Hospital in Eden, N.C., and Novant Health in Winston-Salem, N.C., have signed a shared services agreement to reduce supply chain costs and share corporate resources, according to a News-Record report.
The U.S. Food and Drug Administration has prohibited Ranbaxy Laboratories in Toansa, India, from manufacturing and distributing active pharmaceutical ingredients for FDA-regulated drug products.